Crohn’s Disease

Clinical Trial Info

  • Category

    Current Enrolling Clinical Trials

Inflammatory Bowel Disease (IBD)

Inflammatory bowel disease (IBD) is a term for two conditions (Crohn’s disease and ulcerative colitis) that are characterized by chronic inflammation of the gastrointestinal (GI) tract. Inflammation affects the entire digestive tract in Crohn’s disease and only the large intestine (also called the colon) in ulcerative colitis

Crohn’s symptoms can be constant and isolating. Our new clinical studies are investigating potential treatment options.

Learn more about current Crohn’s disease or Ulcerative Colitis research trials.

ClinicalTrials.gov Study Details
Crohn’s Clinical Trial ABBV M14-431
Clinical Study Protocol M14-431 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy
Crohn’s Clinical Trial ABBV M14-433
Clinical Study Protocol M14-433 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies

ARENA: Principal Investigator: Dr. Munoz
Etrasimod S1P receptor modulator to treat Immune-mediated Inflammatory disorders. for Moderate to Severe Chrons vs Placebo. Study Duration 208 weeks. Pt’s.who Failed Biologic

Treatment or conventional treatment. Etrasimod is a synthetic S1P receptor modulator given orally. 18-80 YOA


Contact Research

Physician Investigator

Photo of Mark Fleisher M.D.
Gastroenterologist Encore Borland Groover Clinical Research
Clinical Research Location 4800 Belfort Road Jacksonville FL 32256 Contact Research: 9046800871
Return to top.

Photo of Juan Carlos Munoz M.D.
Gastroenterologist Encore Borland Groover Clinical Research
Contact Research: 9046800871
Return to top.